Literature DB >> 10644965

Transforming growth factor-beta1 incorporated during setting in calcium phosphate cement stimulates bone cell differentiation in vitro.

E J Blom1, J Klein-Nulend, C P Klein, K Kurashina, M A van Waas, E H Burger.   

Abstract

Growth stimulation of periimplant tissues by growth factors like transforming growth factor-beta1 (TGF-beta1) may increase the indication for and success of implant use. Calcium phosphate as a material for implants or for coating of implants is known for its good biologic interaction with bone. Therefore, calcium phosphate implants combined with TGF-beta1 might improve osseointegration. In this study we hypothesise that the addition of recombinant human TGF-beta1 (rhTGF-beta1) to calcium phosphate cement (CPC) affects the differentiation of bone cells growing on the cement layer. rhTGF-beta1 incorporated during setting in a CPC layer at 20 ng rhTGF-beta1/60 mg cement was found to be gradually released into tissue culturing medium leading to a 20% release after 24 h. Two cell populations were obtained from collagenase-treated fragments of adult rat long bones: preosteoblastic cells, which were released by the collagenase treatment, and osteoblastic cells, which grew from the collagenase-stripped bone fragments. Both cell populations were tested for their osteoblastic characteristic phenotype by measuring their alkaline phosphatase (ALP) activity after vitamin D treatment and cyclic AMP after parathyroid hormone stimulation. After preculture the cells were plated on a layer of CPC containing 0 (control), 10, or 20 ng rhTGF-beta1/60 mg CPC. Bone cell differentiation was analyzed after 10 days by measuring the ALP activity, as well as the protein content of the cell layer. Incorporation of rhTGF-beta1 in the CPC did not change the ALP activity in osteoblastic cells, but a significant (analyzed by multivariate analysis of variance) increase was observed in preosteoblastic cells. Incorporation of 10 ng of rhTGF-beta1 in 60 mg of CPC increased the ALP activity in preosteoblastic cells by threefold and 20 ng rhTGF-beta1/60 mg CPC increased it by fivefold. The total protein content was not affected by rhTGF-beta1 in either of the cell populations. We conclude that rhTGF-beta1 incorporated during setting in CPC stimulates the differentiation of preosteoblastic cells in vitro. These results provide a basis for further studies on the use of this combination as an implant material in vivo. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644965     DOI: 10.1002/(sici)1097-4636(200004)50:1<67::aid-jbm10>3.0.co;2-e

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  6 in total

1.  High-strength, in situ-setting calcium phosphate composite with protein release.

Authors:  Michael D Weir; Hockin H K Xu
Journal:  J Biomed Mater Res A       Date:  2008-05       Impact factor: 4.396

Review 2.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

Review 3.  Prevention and treatment of cancer with aspirin: where do we stand?

Authors:  Boris Pasche; Minghui Wang; Michael Pennison; Hugo Jimenez
Journal:  Semin Oncol       Date:  2014-04-24       Impact factor: 4.929

4.  Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials.

Authors:  Yuwei Wang; Kenny K Tran; Hong Shen; David W Grainger
Journal:  Biomaterials       Date:  2012-09-03       Impact factor: 12.479

5.  Osteoblastic induction on calcium phosphate cement-chitosan constructs for bone tissue engineering.

Authors:  Michael D Weir; Hockin H K Xu
Journal:  J Biomed Mater Res A       Date:  2010-07       Impact factor: 4.396

6.  A novel controlled-release system for antibacterial enzyme lysostaphin delivery using hydroxyapatite/chitosan composite bone cement.

Authors:  Bai Xue; Cheng Zhang; Yihan Wang; Jincheng Wang; Jien Zhang; Min Lu; Guodong Li; Zhizhong Cao; Qingshan Huang
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.